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Endoscopic ultrasound (EUS)-guided tissue acquisition of pancreatic solid tumor requires a strict 
recommendation for its proper use in clinical practice because of its technical difficulty and inva-
siveness. The Korean Society of Gastrointestinal Endoscopy (KSGE) appointed a task force to 
draft clinical practice guidelines for EUS-guided tissue acquisition of pancreatic solid tumor. The 
strength of recommendation and the level of evidence for each statement were graded according 
to the Minds Handbook for Clinical Practice Guideline Development 2014. The committee, com-
prising a development panel of 16 endosonographers and an expert on guideline development 
methodology, developed 12 evidence-based recommendations in eight categories intended to 
help physicians make evidence-based clinical judgments with regard to the diagnosis of pan-
creatic solid tumor. This clinical practice guideline discusses EUS-guided sampling in pancreatic 
solid tumor and makes recommendations on circumstances that warrant its use, technical is-
sues related to maximizing the diagnostic yield (e.g., needle type, needle diameter, adequate 
number of needle passes, sample obtaining techniques, and methods of specimen processing), 
adverse events of EUS-guided tissue acquisition, and learning-related issues. This guideline was 
reviewed by external experts and suggests best practices recommended based on the evidence 
available at the time of preparation. This guideline may not be applicable for all clinical situations 
and should be interpreted in light of specific situations and the availability of resources. It will be 
revised as necessary to cover progress and changes in technology and evidence from clinical 
practice. (Gut Liver 2021;15:354-374)
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INTRODUCTION
Endoscopic ultrasound (EUS)-guided fine-needle aspi-
ration (FNA) plays an essential role in the establishment of 
an accurate tissue diagnosis and tailored treatment plan for 
pancreatic solid tumors, and is associated with few major 
adverse events.1 Diagnosis based on EUS-FNA has relative-
ly high but widely variable sensitivity and specificity (75% 
to 92% and 82% to 100%, respectively), with a diagnostic 
accuracy and adverse events rate ranging from 70% to 
100% and from 0% to 3%, respectively.2-4 With the recent 
introduction of EUS-guided fine needle biopsy (FNB), his-
tological analysis now allows for the differential diagnosis 
of various pancreatic solid tumors. In the current person-
alized medicine era, it is becoming increasingly essential 
to obtain optimal histologic core for molecular analysis.5 
Despite these advances in tissue acquisition of pancreatic 
solid tumors, many aspects still require clinical and tech-
nical standardization. This clinical and technical practice 
guideline for EUS-guided tissue acquisition of pancreatic 
solid tumor includes recommendations on circumstances 
that warrant its use, the technique for obtaining the highest 
possible yield, sample processing method, adverse events 
related to the procedure, and the learning curve of the av-
erage trainee. 
Our purpose was to establish a practical guideline for 
EUS-guided tissue acquisition that applies to the current 
medical practice. The target for this guideline includes 
patients with pancreatic solid tumor requiring tissue diag-
nostic confirmation. We aimed to provide a suitable frame-
work for making decisions regarding the appropriate and 
accurate diagnosis for preoperative evaluation and post-
operative management of patients with pancreatic solid 
tumors. The target audience for this guideline includes cli-
nicians who perform EUS-guided tissue acquisition rang-
ing from general clinicians to physicians that specialize in 
pancreatology, clinical researchers, and health policymak-
ers involved in the diagnosis and treatment of pancreatic 
solid tumors. A summary of the evidence statement and 
recommendations is provided at the end of this paper.
MATERIALS AND METHODS
1. Formation of committee members and stakeholder 
involvement
The Korean Society of Gastrointestinal Endoscopy 
(KSGE) Task Force on Guideline for EUS-guided tissue 
acquisition of pancreatic solid tumor comprised a develop-
ment panel of 16 endosonographers, who were experts in 
this field, and an expert in methodology for guideline de-
velopment. Conflicts of interest were disclosed according 
to the guideline of the KSGE. During the development of 
this guideline, no members of the Task Force were solicited 
or asked about the development activities by other stake-
holders. There was also an internal evaluation panel within 
members of the committee comprising six gastroenter-
ologists, one pathologist, and one statistician in charge 
of methodology for guideline development. Six external 
validation panel members were also asked to conduct a 
full evaluation (Table 1). Then, the guidelines were evalu-
ated and validated by a wide range of additional external 
experts, including the epidemiologist, health care provider, 
clinical physicians, and surgeons. 
2. Selection of key questions
The members of the committee set up the following 
eight items: indication of EUS-guided tissue acquisition 
Table 1. Task Force Team for the Guidelines for EUS-Guided Tissue Acquisition from Solid Pancreatic Tumors
KSGE Clinical Practice Guideline Committee
        President Hoon Jai Chun (in November 2017)
Joo Young Cho (present)
        Congress chairman Soo Teik Lee (in November 2017)
Ho Gak Kim (in November 2018)
Chan Guk Park (present)
        Director and chairperson of the KSGE Task Force Jeong-Sik Byeon
KSGE Task Force on Clinical Practice Guideline for EUS-guided tissue acquisition of pancreatic solid tumor
        Director Se Woo Park
        Development panel director Se Woo Park, Moon Jae Chung
        Development panel members Seong-Hun Kim, Chang Min Cho, Jun-Ho Choi, Eun Kwang Choi, Tae Hoon Lee, Eunae Cho 
        Evaluation panel director Jun Kyu Lee
        Evaluation panel members Tae Jun Song, Jae Min Lee, Jun Hyuk Son, Jin Suk Park, Chi Hyuk Oh 
        External evaluation panel members Dong-Ah Park and her team
Collaborating societies The Korean Society of Gastroenterology
Korean Pancreatobiliary Association
KSGE, Korean Society of Gastrointestinal Endoscopy; EUS, endoscopic ultrasound.
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of pancreatic solid tumor; selection of the appropriate 
needle; the optimal number of needle passes; strategy for 
inadequate or inconclusive pathological results; specific 
endoscopic techniques; methods of specimen processing; 
adverse events and their prevention; and learning-related 
issues. Because the definition of pancreatic solid tumor 
and the significance of diagnosing pancreatic solid tumor 
by image modalities represents the major premise on 
which this guideline is formulated, we did not handle this 
item as a statement. Therefore, key questions (KQs) were 
prepared for the other eight items, and modifications were 
made based on opinions of the internal evaluation panel 
such that there were 12 statements in total. The KQs were 
established through the PICO process; P (population) rep-
resents patients with pancreatic solid tumors; I (interven-
tion) represents main therapeutic interventions including 
EUS-guided tissue acquisition; C (comparison) represents 
main alternative therapeutic interventions to compare with 
the interventions; and O (outcome) represents the useful-
ness of diagnostic performance. 
3. Literature search and selection
For each KQ, a systematic literature search was con-
ducted until December 2017 using PubMed and the Co-
chrane database. A detailed description of keywords and 
search formulas were given for each statement. In addition, 
a manual search was conducted when there were insuf-
ficient research results to refer to. The literature search was 
performed by members of the team of experts for clinical 
practice guideline development who suggested search que-
ries and presented search results in collaboration with the 
committee members. We searched the Cochrane Library, 
EMBASE, KoreaMed, MEDLINE, and the Guideline In-
ternational Network in July 2019. Keywords related to the 
pancreatic solid tumor ((“pancreatic” OR “pancreas” OR 
“pancreato”) AND (“cancer” OR “tumor” OR “carcinoma” 
OR “adenocarcinoma” OR “neoplasm”)), and endoscopic 
ultrasound (EUS)-guided tissue acquisition ((“endoscopic 
ultrasound” OR “EUS” OR “Echoendoscopic”) AND (“as-
piration” OR “biopsy” OR “histologic” OR “pathologic” OR 
“cytologic”)) were used. Different keywords or different 
combinations of keywords were also used based on each 
KQ. 
The exclusion criteria were as follows: (1) studies not 
involving human subjects or the target populations of the 
guideline’s KQs; (2) studies that did not perform an inter-
vention related to the KQs and intervention for compari-
son; (3) studies that were case reports, unpublished studies, 
abstract-only publications, or review articles; (4) studies 
that were published in a language other than English; and 
(5) the original full-text could not be found. In the first 
stage of study selection, duplicate studies were removed. 
For each KQ, titles and abstracts of articles returned from 
our keyword search were examined independently by two 
assigned committee members to exclude irrelevant articles. 
The entire contents of all selected full-texts were then 
screened as per our inclusion and exclusion criteria.6 Two 
independent investigators for each KQ evaluated the stud-
ies for eligibility and resolved any disagreements through 
discussion and consensus. When no agreement could be 
reached, the team leader (S.W.P) of the corresponding sub-
committee made the final conclusion. Moreover, additional 
research was undertaken to identify extra studies through 
the references of the screened articles. The last date of up-
dating our search was March 31, 2020.
4. Evidence assessment and formulating 
recommendations 
Qualitative systematic reviews were conducted to evalu-
ate the risk of biases and heterogeneity of each study. The 
domains of risk of bias included performance bias, selec-
tion bias, attrition bias, detection bias, and other biases. 
The revised Cochrane risk of bias tool was used to evaluate 
randomized controlled trials (RCTs),6,7 and the Newcastle-
Ottawa assessment scale was used to evaluate nonran-
domized studies.6,8 The Quality Assessment of Diagnostic 
Accuracy Studies (QUADAS)-2 tool was used for the study 
of diagnostic test accuracy.9 The members of the commit-
tee determined the level of evidence for each study within 
their allocated field, and the strength of recommendation 
and level of evidence for each statement were determined 
according to the Minds Handbook for Clinical Practice 
Guideline Development 2014. 
The strength of recommendations was graded with 
reference to (1) the quality of the evidence, (2) the homo-
geneity of the study population, (3) risks-benefits analysis, 
and (4) cost analysis. Regarding consensus establishment, 
a total of 12 committee members voted for each proposed 
statement according to the modified Delphi method, 
which uses a scoring system (sum of the score 1–2: non-
consensus, 3: dissatisfaction, 4–5: consensus). The options 
were adopted as confirmative statements if any of the state-
ments achieve a consensus of 2/3 agreement or higher as 
agree or agree strongly (as point 4 or 5). If the proposed 
statements had an agreement <2/3 among 12 committee 
members, either it had to be modified or the strength of 
recommendation had to be amended through discussion 
within the committee; subsequently, voting was repeated 
until a higher agreement above 2/3 was achieved. Accord-
ing to the sum of the score, the grading of recommenda-
tions was divided into two categories, “1: Strong Recom-
mendations” and “2: Weak Recommendations,” which are 
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described as “recommendations” and “suggestions,” respec-
tively.10,11 Table 2 summarizes the recommendations with 
their grades of recommendation and levels of evidence.
5. Review and approval
For an internal review by the KSGE, a total of 34 mem-
bers of the KSGE Steering Committee and 14 members 
from the Insurance Committee of KSGE reviewed the first 
draft using open questions and provided comments. The 
draft was revised according to the comments to ensure bal-
ance and completeness of the guideline. Furthermore, for 
an external review of the guideline, a modified e-Delphi 
mechanism process such as employing the online platform 
was then used for 11 expert panels to produce an evidence-
Table 2. Summary and Strength of Recommendations for EUS-Guided Tissue Acquisition from Solid Pancreatic Tumors
Statement 1: Tissue confirmation is strongly recommended in patients with solid pancreatic tumor who will undergo anti-tumor therapy such 
as chemotherapy or radiotherapy at the unresectable stage, including metastatic or locally advanced lesions (level of evidence: high, grade of 
recommendation: strong). Furthermore, tissue confirmation is also recommended at the resectable stage to exclude benign disease before 
surgical resection and minimize unnecessary surgeries. In addition, tissue confirmation is preferred at the borderline resectable stage for 
determination of appropriate neoadjuvant therapy. It may be mandatory in certain circumstances in which it is difficult to definitively diagno-
sis between malignancy and unusual tumors (e.g., lymphoma, some pancreatic metastases, or autoimmune pancreatitis) (level of evidence: 
moderate, grade of recommendation: weak).
Statement 2: 
2-1. For routine EUS-guided tissue acquisition of pancreatic solid tumors, FNA and FNB needles are equally recommended. When the pri-
mary aim of sampling is to obtain a histologic core tissue specimen (e.g., focal autoimmune pancreatitis or neuroendocrine tumors), 
KSGE recommends using FNB needles (level of evidence: moderate, grade of recommendation: strong).
2-2. Our group suggests that no specific type or diameter of needle has a higher diagnostic accuracy than others in EUS-guided tissue acquisi-
tion for solid pancreatic tumors. However, 22-gauge needles tended to have superior outcomes compared to 19-gauge or 25-gauge needles 
in terms of optimal histologic core procurement and sample adequacy (level of evidence: low, grade of recommendation: weak).
Statement 3: Because ROSE is not available in Korea, our group suggests that 4 needle passes using EUS-guided tissue acquisition may be ad-
equate to achieve appropriate diagnosis in patients with pancreatic tumors. Pancreatic tumors less than 2 cm may require a higher number 
of needle passes. Furthermore, fewer needle passes might be required for the EUS-FNB procedure (level of evidence: low, grade of recom-
mendation: weak).
Statement 4: Repeat EUS-guided acquisition provides a conclusive diagnosis in the majority of cases with indeterminate cytopathological diag-
noses and, therefore, should be strongly recommended ahead of other modalities such as biopsy under CT-guidance or diagnostic surgical 
exploration (level of evidence: moderate, grade of recommendation: strong). Furthermore, K-ras mutation allows increasing diagnostic ac-
curacy for inconclusive samples (level of evidence: low, grade of recommendation: weak).
Statement 5: 
5-1. Our group suggests that routine application of ROSE cannot guarantee an improvement in diagnostic accuracy and performance in terms 
of sensitivity and specificity. Nevertheless, application of ROSE is expected to achieve higher per-case accuracy than non-application (level 
of evidence: low, grade of recommendation: weak).
5-2. The use of a stylet during EUS-guided tissue acquisition does not appear to guarantee any advantages with regards to the adequacy of 
the specimen, diagnostic yield, nor regarding prevention of needle clogging by gut wall tissue (level of evidence: moderate, grade of rec-
ommendation: weak). 
5-3. Our group suggests that routine application of suction is recommended in cases where cellularity is poor, such as fibrotic lesions in 
chronic pancreatitis, whereas it is discouraged in non-fibrotic lesions which may contain necrosis and blood to minimize contamination 
of the cellular sample (level of evidence: moderate, grade of recommendation: weak). Also, the slow-pull-back technique may be more 
effective in terms of adequate tissue acquisition and require fewer needle passes for solid pancreatic tumors (level of evidence: low, 
grade of recommendation: weak).
5-4. Our group suggests that the fanning technique for EUS-guided tissue acquisition offers technically acceptable feasibility and superior 
diagnostic performance, including fewer needle passes required to establish the definite diagnosis, than the standard technique (level 
of evidence: moderate, grade of recommendation: strong). Furthermore, the torque technique, similar to the fanning technique, also 
showed better outcomes regarding optimal histologic core procurement and diagnostic accuracy in comparison with the standard tech-
nique (level of evidence: low, grade of recommendation: weak).
Statement 6: Diagnostic performances are most affected by preparations processing (direct smear, liquid-based cytology, cell block, and his-
tology) and by staining techniques (Papanicolaou methods, Diff-Quik, hematoxylin and eosin, and Giemsa). Furthermore, specialized immu-
nohistochemistry staining aids in the diagnosis of epithelial components with cytologic atypia and in differentiating various tumor cell types. 
The use of immunohistochemistry staining and molecular/genetic assays can enhance the value of oncological predictions and lead to tailor-
made treatments (level of evidence: low, grade of recommendation: weak).
Statement 7: EUS-guided tissue acquisition is a safe intervention with relatively low risks of mortality (0.02%) and morbidity (0.98%). Proce-
dure-related abdominal pain and post-procedure pancreatitis are the most common adverse events. Most unpredictable adverse events are 
mild in severity and self-limiting, while severe adverse events are very rare (level of evidence: moderate, grade of recommendation: strong).
Statement 8: In regard to EUS, the average trainee has to perform at least 225 EUS examinations with a total of 50 EUS-guided tissue acquisi-
tion procedures for achievement of competency in EUS-guided FNA or FNB (level of evidence: low, grade of recommendation: weak).
EUS, endoscopic ultrasound; FNA, fine-needle aspiration; FNB, fine needle biopsy; KSGE, Korean Society of Gastrointestinal Endoscopy; ROSE, 
rapid on-site evaluation; CT, computed tomography.
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based consensus. This consensus consisted of two main 
rounds of web-based voting, using a custom-built online 
voting platform scoring each using a 5-point scale with up-
dated iterations of the statements and evaluative text based 
on feedback after each round. Following the first round 
of voting, the statements that achieved a consensus of 2/3 
agreement or higher as agree or agree strongly (as point 4 
or 5) were accepted as final statements and recommenda-
tions. The statements that did not achieve 2/3 were entered 
into the second round of voting after appropriate revision 
based on discussions during the e-Delphi mechanism pro-
cess. The statements and recommendations that did not 
reach the 2/3 consensus agreement following two rounds 
of voting were removed.
6. Provision of the guideline and plans for next 
updates
For universal provision and distribution of the practi-
cal guideline, we plan to publish the guideline in Clinical 
Endoscopy, the Korean Journal of Gastroenterology, the 
Korean Journal of Pancreas and Biliary Tract, and Gut and 
Liver. We will also upload the guideline on the website 
of KSGE and submit it to the Korean Medical Guideline 
Information Center. Because the rapid distribution of this 
guideline to endosonographers through the databases 
is expected to be difficult, the KSGE will distribute the 
guideline for free via various routes including emails, and 
will actively promote it in academic conferences, seminars, 
and workshops. Current recommendations in the practical 
guideline are based on up to date research and will be re-
vised regularly with new evidence related to technical and 
instrumental advances, with the KSGE Guideline Commit-
tee taking a key role.
7. Limitations and legal matters
It is not anticipated that treatment decisions will be 
made using this practical guideline without first consider-
ing the specific conditions of individual patients. Medical 
conditions such as demographic background, underlying 
comorbidities, clinical stage, and economic environment 
vary among individuals. Furthermore, this guideline is not 
intended to establish an absolute diagnostic or therapeutic 
standard that physicians should use to manage patients in 
real clinical settings but aims to assist physicians in mak-
ing evidence-based clinical judgments with regard to the 
diagnosis of pancreatic solid tumor. It is impossible for the 
guideline development committee to consider the specific 
conditions of each individual patient when formulating 
recommendations. Thus, this practical guideline should 
not be used to support legal judgments in the assessment 
of the appropriateness of individual medical practice.
STATEMENTS
1. The indications for EUS-guided tissue acquisition 
in pancreatic solid tumor: when to puncture? 
Recommendation
Tissue confirmation is strongly recommended in pa-
tients with solid pancreatic tumors who will undergo 
anti-tumor therapy such as chemotherapy or radio-
therapy at the unresectable tumors, including metastatic 
or locally advanced lesions (level of evidence: high, 
grade of recommendation: strong). Furthermore, tissue 
confirmation is also recommended at the resectable tu-
mors to exclude benign disease before surgical resection 
and minimize unnecessary surgeries. In addition, tissue 
confirmation is preferred at the borderline resectable 
stage for the determination of appropriate neoadjuvant 
therapy. It may be mandatory in certain circumstances 
in which it is difficult to definitively diagnose between 
pancreatic ductal adenocarcinoma and unusual tumors 
(e.g., lymphoma, some pancreatic metastases, or au-
toimmune pancreatitis) (level of evidence: moderate, 
grade of recommendation: weak).
It is essential that the indications for EUS-guided tis-
sue acquisition can provide information on the potential 
treatment strategy of patients with pancreatic solid tumor. 
Furthermore, endoscopists should consider the technical 
feasibility in terms of the distance from the echoendoscope 
to the target lesion as well as blood vessel location during 
needle puncture. In some countries, tissue confirmation of 
specific cell types is mandatory before anti-tumor therapy 
such as chemotherapy or radiotherapy to ensure effective 
response as well as conformance with the policy of the 
country’s national health insurance system. Recently, the 
European Society of Gastrointestinal Endoscopy (ESGE) 
guidelines12 on EUS-guided tissue acquisition attempted 
to establish some recommendations by reporting the 
suggested and accepted indications for this procedure. 
Generally, EUS-guided tissue acquisition provides high 
diagnostic accuracy (sensitivity and specificity, 85% to 89% 
and 96% to 99%, respectively, according to three meta-
analyses13-15) with a relatively low negative predictive value 
for the diagnosis of pancreatic malignancy, and is also 
associated with a very low incidence of adverse events, 
even in long-term adverse events such as tumor seeding.16 
Before this, tissue confirmation had not generally been 
recommended prior to curative resection for potentially 
resectable pancreatic tumors inoperable patients. Although 
the predominant cell type is adenocarcinoma, the differen-
tial diagnosis of a solid pancreatic tumor can include other 
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definite malignant tumors such as lymphoma, squamous 
cell carcinoma, and neuroendocrine tumors, potentially 
the premalignant tumors such as a gastrointestinal stromal 
tumor, solid pseudopapillary tumor, other metastatic ma-
lignancies from kidney, colon, lung or other organs, and 
even benign lesions such as autoimmune pancreatitis and 
focal mass-forming chronic pancreatitis. Fig. 1 shows sev-
eral EUS findings from solid pancreatic tumors other than 
the typical pancreatic ductal adenocarcinoma. In addition, 
pancreatic tumor with cystic components such as intrapap-
illary mucinous neoplasm, mucinous cystadenoma, serous 
cystadenoma, and even simple cyst or pseudocyst has been 
estimated to account for approximately 6% of patients 
undergoing pancreatic resection.17 Therefore, to minimize 
unnecessary surgeries, a pretreatment tissue confirmation 
is mandatory and recommended in most cases: (1) unre-
sectable pancreatic tumor; (2) resectable/borderline resect-
able pancreatic tumor; (3) autoimmune pancreatitis or 
mass-forming chronic pancreatitis; or (4) neuroendocrine 
pancreatic tumors and other pancreatic tumors.
2. Which needle is recommended with regard to 
diagnostic yield, adverse events, and ease to use 
depending on the location of the lesion?
1) Should biopsy needles (FNB needles) rather than 
standard needles (FNA needles) be used?
Recommendation
For routine EUS-guided tissue acquisition of pancre-
atic solid tumors, FNA and FNB needles are equally 
recommended. When the primary aim of sampling is to 
obtain a histologic core tissue specimen (e.g., focal auto-
immune pancreatitis or neuroendocrine tumors), KSGE 
recommends using FNB needles (level of evidence: 
moderate, grade of recommendation: strong).
2) Should 19-gauge vs 22-gauge vs 25-gauge needles 
be used? 
Recommendation
Our group suggests that no specific type or diameter 
of the needle has higher diagnostic accuracy than others 
in EUS-guided tissue acquisition for solid pancreatic tu-
mors. However, 22-gauge needles tend to have superior 
outcomes compared to 19-gauge or 25-gauge needles 
in terms of optimal histologic core procurement and 
sample adequacy (level of evidence: low, grade of rec-
ommendation: weak).
There are various types and diameters of needle used in 
EUS-guided tissue acquisition for solid pancreatic tumors 
in the market. Furthermore, a new type of needle specially 
designed to procure histologic core preserving intact his-
tologic architecture for suitable pathological evaluation has 
been introduced recently. These devices, collectively called 
FNB needles, has the unique feature of a needle tip which 
has either a side-slot (core trap) or a special geometry of 
the cutting tip (Table 3).18 
EUS-guided tissue acquisition for cytopathologic evalu-
ation through FNA or FNB using specially designed core 
Fig. 1. Endoscopic ultrasound image of different solid pancreatic tumors (arrows). (A) Solid lesion located in the pancreatic head, corresponding 
to pancreatic ductal adenocarcinoma. (B) Pancreatic neuroendocrine tumor located in the pancreatic tail. (C) Insulinoma located in the pancreatic 
tail. (D) Solid pseudopapillary tumor located in the pancreatic tail. (E) Mass-forming chronic pancreatitis located in the pancreatic neck. (F) Mass-
forming autoimmune pancreatitis located in the pancreatic head with bile duct obstruction.





Gut and Liver, Vol. 15, No. 3, May 2021
360  www.gutnliver.org
needles has become a key technique in the diagnosis of 
solid pancreatic tumors.19 Standard needles without these 
reinforcement geometries are here classified as FNA nee-
dles. Needles with a side port (EZ-Shot 3 with side port, 
Olympus) were classified as FNA needles because the side 
port of this needle system does not have a bevel design for 
cutting the tissue.18 A recent network meta-analysis19 con-
sisting of 15 parallel trials and 12 cross-over studies dem-
onstrated that traditional pairwise meta-analyses failed to 
report superiority in the diagnostic accuracy of any needle 
over another in a head-to-head comparison. In detail, 
there was no difference regarding the diagnostic accuracy 
between the 22-gauge FNB and FNA approach (relative 
risk [RR], 1.02; 95% confidence interval [CI], 0.97 to 1.08) 
or between the 25-gauge and 22-gauge FNA needle (RR, 
1.03; 95% CI, 0.98 to 1.07). Furthermore, no differences 
were noted between the 22-gauge FNA and 19-gauge FNA 
needles (RR, 1.07; 95% CI, 0.78 to 1.46). In this meta-
analysis, no significant difference was reported between 
the two types of 22-gauge FNB needles (Fork-tip vs Fran-
seen: RR, 0.96; 95% CI, 0.87 to 1.06). Similar to the results 
of direct meta-analyses, there was no significant difference 
in diagnostic accuracy between FNB and FNA needles, or 
22-gauge and 25-gauge needles. 
In regard to sample adequacy, 22-gauge FNB had sig-
nificantly better sample adequacy than 25-gauge FNA (RR, 
0.79; 95% CI, 0.68 to 0.92) in the direct meta-analysis, 
whereas 22-gauge FNA was more likely to obtain an ad-
equate sample compared with 19-gauge FNA needles (RR, 
1.13; 95% CI, 1.00 to 1.28). However, the results of net-
work meta-analyses did not indicate that any of the tested 
needles were superior to another in terms of obtaining an 
adequate sample. 
In regard to histologic core procurement rate, 25-gauge 
FNB had a significantly superior outcome than 25-gauge 
FNA (RR, 1.17; 95% CI, 1.00 to 1.36) according to a direct 
meta-analysis.20 Furthermore, 22-gauge FNB was found 
to be superior to 25-gauge FNA (RR, 4.56; 95% CI, 2.49 to 
8.35). In other direct comparisons, the histologic core pro-
curement rate was comparable for different needles includ-
ing the 22-gauge FNB and 22-gauge FNA needle (RR, 1.01; 
95% CI, 0.89 to 1.15). 
3. What is the optimal number of needle passes when 
rapid on-site cytologic evaluation (ROSE) is not 
available?
Recommendation
Because ROSE is not available in Korea, our group 
suggests that 4 needle passes using EUS-guided tissue 
acquisition may be adequate to achieve appropriate di-
agnosis in patients with pancreatic tumors. Pancreatic 
tumors less than 2 cm may require a higher number of 
needle passes. Furthermore, fewer needle passes might 
be required for the EUS-FNB procedure (level of evi-
dence: low, grade of recommendation: weak).
The optimal number of needle passes for accurate diag-
nosis of solid pancreatic tumors has been the subject of de-
bate. The execution of more needle passes than necessary 
may cause potential procedure-related adverse events and 
also a longer procedure time.21 In contrary to this, carrying 
out a suboptimal number of needle passes may increase 
the rate of false-negative results and lead to unnecessary 
expenses due to repeat interventions. 
Per-pass analyses from recent prospective trials21-25 
have demonstrated that 3 to 4 passes with a standard FNA 
needle or 2 to 3 passes with an FNB needle with a reversed 
bevel system are required to establish optimal sampling 
for pancreatic solid tumors; this produces a sensitivity for 
Table 3. Needles Available on the Market in Korea for Use in EUS-Guided Tissue Acquisition from Solid Pancreatic Tumors18
Manufacturer Model Needle type Needle diameter (gauge)





























*A newly marketed needle has been designed with a core trap and bevel system to increase diagnostic yield and enhance the procurement of the 
histologic core, while other gauge needles (19, 22, and 25 gauge) have a reversed bevel system; †A newly marketed needle has been designed with 
a core trap and bibevel system to increase diagnostic yield and enhance the procurement of the histologic core.
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malignancy of more than 90%. According to one recent 
study, the cumulative sensitivity is significantly inferior for 
tumors ≤2 cm than for tumors >2 cm, based on 4 passes 
with a standard FNA needle. More than 4 needle passes 
significantly improved the diagnostic sensitivity, even for 
smaller tumor sizes.21 Recently, needle designs have mark-
edly evolved to optimize the acquisition of histologic core 
in EUS-guided tissue acquisition (i.e., ProCore, Acquire 
and SharkCore needle). Several prospective comparative 
studies21-25 between FNB and conventional FNA needles 
have revealed that fewer needle passes are required for di-
agnostic confirmation when using an FNB needle.
4. How we do in cases with inadequate or 
inconclusive pathological results? Repeat EUS-
guided tissue acquisition?
Recommendation
Repeat EUS-guided acquisition provides a conclusive 
diagnosis in the majority of cases with indeterminate 
cytopathological diagnoses and, therefore, should be 
strongly recommended ahead of other modalities, such 
as biopsy under computed tomography-guidance or 
diagnostic surgical exploration (level of evidence: mod-
erate, grade of recommendation: strong). Furthermore, 
the K-ras mutation can be an available option to in-
crease the diagnostic accuracy for inconclusive samples 
(level of evidence: low, grade of recommendation: 
weak).
The Papanicolaou Society of Cytopathology developed 
a set of guidelines for standardized terminology and no-
menclature of pancreatobiliary cytology specimens in 2014 
(Table 4).26 It emanates from expert opinions, a systematic 
review of the literature, international discussions among 
pathologists at several meetings during an 18 month, and 
synthesized conclusion from online conferences on the 
draft document on the Papanicolaou Society of Cytopa-
thology web site (www.papsociety.org). Repeat EUS-guided 
tissue acquisition appears to be a reasonable option for an 
inconclusive pathologic result for suspected pancreatic ma-
lignancy.27,28 Eloubeidi et al.29 suggested the usefulness of 
repeat EUS-guided tissue acquisition for inconclusive in-
dex pathologic results. Among 24 (4.6%) patients who un-
derwent repeat EUS-guided tissue acquisition, a true final 
diagnosis could be determined in 20 patients, with an ac-
curacy of 84%. In another multicenter retrospective cohort 
study,30 292 cases with adequate follow-up among a total 
of 4,522 EUS-FNA procedures were assigned to “atypical” 
or “suspicion of malignancy” categories. The proportion 
of malignancy in “atypical” and “suspicion of malignancy” 
categories were 79.2% and 96.3%, respectively. If the “sus-
picion of malignancy” category was defined as malignancy 
and the “atypical” category was defined as a benign disease, 
the positive predictive value was 96.3% (95% CI, 92.6 to 
98.5), and the negative predictive value was 20.8% (95% CI, 
13.4 to 30.0). Thus, the authors demonstrated that defining 
“suspicion of malignancy” categorized tumors as malignant 
optimizes the diagnostic sensitivity and specificity. 
Furthermore, K-ras mutation analysis can be another 
useful option for differentiation of pancreatic mass lesions 
and may complement other diagnostic tools, especially 
when the results of EUS-FNA are inconclusive. In one 
meta-analysis,31 the author reported that the estimated 
sensitivity and specificity of K-ras gene analysis alone were 
76.8% and 93.3%, respectively, and those of combined 
EUS-FNA plus K-ras mutation analysis were 88.7% and 
92%, respectively. Overall, applying K-ras mutation analy-
sis to patients with inconclusive EUS-FNA results may 
reduce the false-negative rate to approximately 50%, the 
false-positive rate to approximately 10%, and the repeat-
biopsy rate from 12.5% to 6.8%. Although K-ras mutation 
analysis can be useful for cases with inconclusive results 
and spare unnecessary repetition of EUS-guided tissue 
acquisition, it is not always commercially available in many 
centers and should be cautiously interpreted within the 
clinical context.31 
5. Sample obtaining techniques
1) Should ROSE always be used?
Recommendation
Our group suggests that routine application of ROSE 
cannot guarantee an improvement in diagnostic accu-
racy and performance in terms of sensitivity and speci-
ficity. Nevertheless, application of ROSE is expected to 
achieve higher per-case accuracy than non-application 
(level of evidence: low, grade of recommendation: 
weak).
The diagnostic accuracy of EUS-guided tissue acquisi-
tion under ROSE is reported to be higher than 90% in 
most studies;32-35 however, comparable results have also 
been reported from some trials without ROSE. In one 
recent meta-analysis,36 authors found that there was no 
indication that the application of ROSE improved the di-
agnostic yield (risk difference [RD], 0.04; 95% CI, 0.05 to 
0.13). Therefore, routine application of ROSE could not 
guarantee superior outcomes in clinical practice at tertiary 
care centers. In samples where the diagnosis was properly 
performed, and malignancy was defined as samples cat-
egorized as “highly suggestive” and “definitive malignancy,” 
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there was no significant difference in the rate of malignant 
diagnoses when ROSE was and was not applied (RD, 0.08; 
95% CI, 0.09 to 0.25). Therefore, the results have shown 
that the application of ROSE does not provide superior 
outcomes in terms of the impact of ROSE on diagnostic 
performance. Furthermore, it has been reported that ap-
plying ROSE does not also have a beneficial effect on cel-
lular yield. Thus, the above finding seems to be reasonable 
since a similar cellular yield should result in comparable 
diagnostic efficacy.36 
However, for a given sample adequacy rate and the 
number of needle passages, ROSE is expected to have 
higher per‐case accuracy than sampling without ROSE.37 
In other words, trials with ROSE have demonstrated a 
higher per‐case diagnostic accuracy than trials without 
ROSE. This suggests that the relationship between per‐case 
diagnostic accuracy and needle passes depends on the use 
of ROSE. 
2) Should the needle stylet be used?
Recommendation
The use of a stylet during EUS-guided tissue acquisi-
tion does not appear to guarantee any advantages with 
regards to the adequacy of the specimen, diagnostic 
yield, nor regarding prevention of needle clogging by 
gut wall tissue (level of evidence: moderate, grade of 
recommendation: weak).
Table 4. Standardized Terminology and Nomenclature for Pancreatobiliary Cytology Specimens in 201426 
Category Nomenclature Definition
Category I Non-diagnostic A non-diagnostic cytology specimen is one that provides no diagnostic or useful information about the solid 
or cystic lesion sampled; for example, an acellular aspirate of a cyst without evidence of a mucinous etiol-
ogy such as thick colloid-like mucus, elevated CEA or KRAS/GNAS mutation (see Category IV). Any cellular 
atypia precludes a non-diagnostic report.
Category II Negative  
(for malignancy)
A negative cytology sample is one that contains adequate cellular and/or extracellular tissue to evaluate or 
define a lesion that is identified on imaging. When using the negative category, one should give a specific 
diagnosis when practical, including: 







Category III Atypical The category of atypical should only be applied when there are cells present with cytoplasmic, nuclear, or 
architectural features that are not consistent with normal or reactive cellular changes of the pancreas or 
bile ducts and are insufficient to classify them as a neoplasm or suspicious for a high-grade malignancy. 
The findings are insufficient to establish an abnormality explaining the lesion seen on imaging. Follow-up 
evaluation is warranted.
Category IV Neoplastic: benign This interpretation category connotes the presence of a cytological specimen that is sufficiently cellular and 
representative, with or without the context of clinical, imaging, and ancillary studies, to be diagnostic of a 
benign neoplasm.
Neoplastic: other This interpretation category defines a neoplasm that is either premalignant such as intraductal papillary 
neoplasm of the bile ducts, intraductal papillary mucosal neoplasms, or mucinous cystic neoplasm with 
low, intermediate, or high-grade dysplasia by cytological criteria, or a low-grade malignant neoplasm 
such as well-differentiated primitive neuroectodermal tumor or solid-pseudopapillary neoplasm. While 
mucinous epithelium in biliary brushing specimens may indeed represent a neoplastic change, given the 
lack of evidence-based literature on the cytological interpretation, histology and management of these le-
sions, low-grade mucinous change of biliary epithelium will remain in the “atypical” rather than “neoplas-
tic” category.
Category V Suspicious  
(for malignancy)
A specimen is suspicious for malignancy when some, but an insufficient number of the typical features of 
a specific malignant neoplasm are present; mainly pancreatic adenocarcinoma. The cytological features 
raise a strong suspicion for malignancy, but the findings are qualitatively and/or quantitatively insufficient 
for a conclusive diagnosis, or tissue is not present for ancillary studies to define a specific neoplasm. The 
morphologic features must be sufficiently atypical that malignancy is considered more probable than not.
Category VI Positive for  
malignancy
A group of neoplasms that unequivocally display malignant cytologic characteristics and include pancreatic 
ductal adenocarcinoma and its variants; cholangiocarcinoma, acinar cell carcinoma, high-grade neuroen-
docrine carcinoma (small cell and large cell), pancreatoblastoma, lymphomas, sarcomas and metastases 
to the pancreas.
CEA, carcinoembryonic antigen; KRAS, Kirsten rat sarcoma viral oncogene homolog; GNAS, guanine nucleotide-binding protein/α-subunit.
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Regarding sample adequacy, the pooled data from a 
recent meta-analysis38 demonstrated that there were no 
significant differences between groups in which the stylet 
was or was not used, although one study39 showed superior 
adequacy of the sample without the stylet. Furthermore, 
there were no differences in the cellularity between groups 
in which the stylet was or was not used despite the theo-
retical advantage of the stylet preventing blockage or con-
tamination of the needle by the intestinal mucosa.38 In one 
prospective RCT of 550 lesions in which the performance 
of EUS-FNA with or without a stylet was compared, Wani 
et al.40 concluded that there was no significant difference 
between groups in which the stylet was or was not used 
in terms of sample cellularity. This lack of a significant 
difference among several studies may be attributed to het-
erogeneity in the cytopathologists’ definitions of sample 
adequacy and cellularity, although predefined criteria were 
used to compare the cytopathologic characteristics of the 
specimens and the cytopathologists were blinded to the 
specimen procurement technique. Furthermore, there 
may have been intra- and inter-observer agreement vari-
ability among cytopathologists in the assessment of EUS-
FNA specimens. Additionally, the use of a stylet did not 
change the contamination rate nor the frequency of bloody 
and/or inadequate samples despite the theory that using a 
stylet will prevent tissue from blocking the needle tip and/
or contamination of the sample before entering the FNA 
target lesion.39
3) Should the no-suction, slow-pull-back, standard (5–10 
mL) suction, high negative pressure, or wet suction 
method be used?
Recommendation
Our group suggests that routine application of suction 
is recommended in cases where cellularity is poor, such 
as fibrotic lesions in chronic pancreatitis, whereas it is 
discouraged in non-fibrotic lesions which may contain 
necrosis and blood to minimize contamination of the 
cellular sample (level of evidence: moderate, grade of 
recommendation: weak). Also, the slow-pull-back tech-
nique may be more effective in terms of adequate tissue 
acquisition and require fewer needle passes for solid 
pancreatic tumors (level of evidence: low, grade of rec-
ommendation: weak).
Theoretically, the application of suction on the needle 
mount was a standard practice based on the understand-
ing that negative pressure would increase cellularity. One 
RCT,41 comparing EUS-FNA with and without suction, 
demonstrated that suction resulted in superior diagnostic 
outcomes in terms of higher sensitivity and lower blood 
contamination rates, although the proportion of pancreatic 
tumors in this study was less than 20% among the various 
included lesions. Another recent RCT,42 comparing only 
pancreatic solid tumor samples acquired with and without 
suction, found that the application of suction resulted in 
higher cellularity and sensitivity but also a higher blood 
contamination rate. Although the effectiveness of suction 
has been demonstrated in several trials, it can decrease 
the sample quality due to the increased blood contamina-
tion. Puri et al.41 found that the suction technique to be 
also associated with an increased number of microscopic 
slides (17.8±7.1 vs 10.2±5.5; p=0.001) and higher blood-
contamination rate when using a 22-gauge needle. An-
other study,42 assessing the results of 324 samples from 81 
patients, identified a significantly higher diagnostic yield 
(85.2% vs 75.9%; p=0.004), sensitivity (82.4% vs 72.1%; 
p=0.005), cellularity (p<0.001), and blood-contamination 
(p<0.001) in the suction group, with no significant differ-
ences in terms of specificity (96.8% vs 100%). 
As an alternative to suction, the slow-pull-back tech-
nique was recently introduced for EUS-FNA or FNB of 
solid pancreatic lesions.23,43,44 In contrast to standard suc-
tion techniques, this technique minimizes negative pres-
sure by removing the stylet from the needle slowly and 
continuously.45 In a recent RCT46 comparing the slow-
pull-back technique, standard negative-suction technique 
after stylet removal, and non-suction technique after stylet 
removal for EUS-FNB, the negative-suction technique had 
a higher blood contamination rate and did not increase the 
rate of core-tissue acquisition. The authors demonstrated 
that the slow-pull-back technique provided greater cel-
lularity with less blood contamination compared with the 
other techniques, although there was no significant differ-
ence in the core-tissue diagnostic adequacy for malignancy 
between the groups. Furthermore, the slow-pull-back 
technique was associated with increased diagnostic ac-
curacy. In another prospective study,47 the slow-pull-back 
technique, compared to the standard suction technique, 
provided faster and more cost-effective results due to lower 
blood contamination and decreased the number of slides 
while guaranteeing comparable results in terms of diagnos-
tic yield, cellularity, and sufficient histological samples. 
4) Should the fanning technique be used rather than the 
standard technique? 
Recommendation
Our group suggests that the fanning technique for 
EUS-guided tissue acquisition offers technically ac-
ceptable feasibility and superior diagnostic outcomes, 
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including fewer needle passes required to establish the 
definite diagnosis, than the standard technique (level of 
evidence: moderate, grade of recommendation: strong). 
Furthermore, the torque technique, similar to the fan-
ning technique, also showed better outcomes regarding 
optimal histologic core procurement and diagnostic ac-
curacy in comparison with the standard technique (level 
of evidence: low, grade of recommendation: weak).
Since its introduction in 2013,24 the fanning technique 
has emerged as a standard technique for EUS-guided tis-
sue acquisition of pancreatic solid tumors. This technique 
is based on the targeting of multiple areas within the mass 
during to-and-fro movements of the needle using the up/
down knob of the endoscope on each needle pass. Bang 
et al. reported that the fanning technique required fewer 
passes than the standard technique for an accurate di-
agnosis; however, this trial failed to show a difference in 
diagnostic accuracy between the fanning and standard 
techniques (96.4% and 76.9%). Theoretically, the applica-
tion of the fanning technique can increase the likelihood 
of achieving a true diagnosis under ROSE on the first pass, 
thereby reducing the risk of inconclusive results. Moreover, 
the fanning technique has no additional risk or financial 
costs. However, the evidence is limited to only one study 
by Bang et al.24 that revealed some advantages with respect 
to the number of needle passes and achievement of a true 
diagnosis but failed to verify a significant impact of the 
technique on diagnostic outcomes. 
Seeking another maneuver with equal or superior di-
agnostic outcomes as the fanning technique without its 
limitations, Park et al.48 invented an alternative and similar 
technique called the “torque technique.” Torque is applied 
by twisting the body of the echoendoscope to the right 
(clockwise) or left (counter-clockwise) without using the 
left/right control knob. In that study, the authors demon-
strated that the torque technique was significantly superior 
to the standard technique with respect to sensitivity and 
diagnostic accuracy. In addition, this technique had a su-
perior procurement rate of histologic core tissue and more 
optimal histologic cores compared to the standard tech-
nique.
6. Methods of specimen processing 
Recommendation
Diagnostic performances are most affected by prepa-
ration processing (direct smear, liquid-based cytology 
[LBC], cell block, and histology) and by staining tech-
niques (Papanicolaou methods, Diff-Quik, hematoxylin 
and eosin, and Giemsa). Furthermore, specialized im-
munohistochemistry (IHC) staining aids in the diagno-
sis of epithelial components with cytologic atypia and in 
differentiating various tumor cell types. The use of IHC 
staining and molecular/genetic assays can enhance the 
value of oncological predictions and lead to tailor-made 
treatments (level of evidence: low, grade of recommen-
dation: weak).
1) Which technique should be used when preparing/
processing samples? Smear cytology, LBC, cell 
block, or histologic preparations?
Diagnostic performance differs by cytologic or histo-
logic sample preparations (smear, rapid cytology, LBC, cell 
block, and histology) and by staining methods.49 Ideally, 
samples from solid pancreatic tumors should be examined 
by both histological and cytological evaluation. 
(1) Smearing and rapid cytology of EUS-FNA samples 
Direct smear facilitates rapid staining and cytological 
diagnosis; thus, is an essential step in processing EUS-FNA 
specimens from pancreatic tumors. The assistant nurse 
places the stylet into the needle channel to extrude the 
aspirated sample onto the slide. Appropriate quantities of 
acquired sample material should be mounted on the slide 
for inspection of optical properties of the optimal speci-
men. Applying large quantities of the sample at once can 
lead to thick smears (with cells obscured within clusters) 
or clotting artifacts, while watery or small quantities of 
sample do not smear well on the slide causing air-drying 
artifacts.50 Insufficient sample quantities, which cannot 
pick up the whitish component, can be processed by the 
cytospin method. In this method, the sample should first 
be immersed in saline and then centrifuged at 2,000–3,000 
rpm for 2 to 3 minutes before being applied to the slide.51 
This technique involves separating the sample into mul-
tiple small aliquots as well as treatment with a hemolytic 
agent and mucus softener. This is favorable as it allows for 
optimal sample preparation with adequate cellularity and 
minimal artifacts.
When smear specimens are made using two slide glass-
es, usually one slide is prepared using the conventional air-
dried method for rapid cytology with Diff-Quik, whereas 
the other slide is fixed in ethanol for later staining using 
Papanicolaou and hematoxylin and eosin stain.52 Diff-
Quik, a rapid version of Giemsa and Papanicolaou stain-
ing, allows for rapid cytological analysis in under a minute, 
even with watery samples containing an abundance of 
exfoliated cells.50 
(2) Liquid-based cytology
Almost all false-negative cytologic results are due to 
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errors in sampling, preparation of the sample, and inter-
pretation of the sample. For this reason, LBC is an effective 
technique for sample preparation which can be manipu-
lated automatically within only 2 to 4 minutes per sample 
after the acquisition of cytologic materials.53 The results of 
comparisons between the diagnostic performance of LBC 
and smears for pancreatic cancer are conflicting. While 
Siddiqui et al.54 found LBC to be superior (LBC vs smear; 
91% vs 58%), Qin et al.55 found the techniques to be simi-
lar (LBC vs smear; 73.3% vs 70%), and others found LBC 
to be inferior56-58 (LBC vs smear; 61.7%–75.0% vs 91.6%–
97.9%). However, there was a consensus that LBC speci-
mens showed clearer backgrounds. LBC has the advantage 
of reducing false-negative results because it provides better 
specimen preservation, a clearer background with less mu-
cin, necrotic material, and inflammatory cells, and higher 
cellularity, by reducing artifacts and extracellular elements 
compared with conventional smear cytology. Furthermore, 
prepared samples from LBC can be used for genetic analy-
sis and IHC to provide further cytologic information.
(3) Cell block 
The cell block is an effective technique that overcomes 
the disadvantages of conventional smear cytology and can 
lead to a definite diagnosis through IHC and molecular 
assays. Various cell block techniques have been developed 
over time: the traditional manual, involving rinsing the 
sample with 50% ethanol; the sodium alginate method, in-
volving fixing the sample in 10% formalin and 1% sodium 
alginate; and the novel Cellient Automated Cell Block 
System (Hologic Inc). All methods involve embedding the 
collected cell pellets in paraffin and cutting thin 3 to 5 µm 
sections before staining.59 Sample prepared by cell block 
can be applied to IHC and specific molecular assays to dif-
ferentiate between malignant and benign lesions and to de-
termine tumor phenotypes. In one study60 comparing the 
diagnostic abilities of the cell block and smear cytology us-
ing 33 pancreatic tumors or lymph node samples acquired 
through EUS-FNA, the cell block technique with IHC was 
superior to smear cytology in regard to sensitivity (92% vs 
60%; p=0.02) and accuracy (94% vs 61%; p=0.003). 
(4) Histology of EUS-FNA/B samples
Recent technical and instrumental improvements 
in EUS-FNB for pancreatic solid tumors have enabled 
adequate histologic sampling, even using 22-gauge or 
25-gauge needles. According to a recent network meta-
analysis,19 two RCTs reported that 25-gauge FNB was supe-
rior to 25-gauge FNA (RR, 1.17; 95% CI, 1.00 to 1.36)20 and 
that 22-gauge FNB was more predominant than 25-gauge 
FNA (RR, 4.56; 95% CI, 2.49 to 8.35)61 in regards to opti-
mal histologic core procurement. They also reported that 
the 22-gauge FNB and 22-gauge FNA needles (RR, 1.01; 
95% CI, 0.89 to 1.15) did not differ in terms of optimal 
histologic core procurement. IHC and molecular assays 
can be applied more easily to FNB samples than to samples 
from cytology or cell block. Ideally, EUS-guided tissue ac-
quisition of pancreatic tumors should routinely include a 
histological evaluation by biopsy in addition to cytology.
2) Special handling (IHC, telecytology, ancillary 
molecular analysis, and chemosensitivity): how to do 
it and in which cases?
IHC staining focuses on the diagnosis of epithelial com-
ponents with histological atypia and differential diagnosis 
of various tumors such as mass-forming chronic pan-
creatitis, pancreatic neuroendocrine tumor (PNET), and 
autoimmune pancreatitis through preserving histologic 
architecture. Genetic analysis can aid in tailored treatment 
in individuals with pancreatic cancer and prediction of 
prognosis. Telecytology, which is a remote cytopathology 
diagnostic system based on online transmitted microscope 
images, enables real-time diagnosis of the samples by ex-
pert cytopathologists. 
(1) IHC and special staining
IHC can be applied to histologic cores from EUS-FNB, 
cell block, and even LBC. It can differentiate benign and 
malignant lesions and reduces false negatives by staining 
for tumor suppressor gene proteins (e.g., TP53 or E-cad-
herin)62 and tumor-associated proteins (e.g., mesothelin, 
S100P or fascin).63 Furthermore, IHC can determine tumor 
aggressiveness or predict the clinical behavior of PNET 
using the Ki-67 index on large prepared pieces of tumor 
tissue from EUS-FNB (>2,000 cells).64 In addition, IHC can 
also identify the phenotype of the tumor and eventually 
the cell origin (Table 5).49 
(2) Telecytology or telepathology
The most ideal system for the rapid cytological diag-
nosis of samples from EUS-FNA is ROSE. As mentioned 
earlier, however, the usefulness of the ROSE system is 
limited both in terms of time required and availability of 
technology, even in an experienced tertiary hospital. As a 
substitute for ROSE, telecytology was introduced in 1997 
by the International Academy of Cytology Task Force sum-
mary to save time and labor of cytopathologists and to 
enable real-time analysis of samples from EUS-FNA per-
formed at remote locations, even at field hospitals.65 It is a 
remote cytopathology diagnostic system based on online 
transmitted microscope images. It consists of bidirectional 
communication using an internet connection; physicians 
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process samples from each pass of a EUS-FNA using Diff-
Quik smear and selects several representative cytological 
images. Thereafter, the images are transmitted to the pa-
thologist’s computer through a network system. Cytopa-
thologists then report the results of the images by phone. 
Recent trials have demonstrated that each image can be 
transmitted within 0.5 to 3 seconds with high resolution.66 
When combining the pre-screen time, scan time, and diag-
nosis time, telecytology takes an average of approximately 
12 minutes per sample.66 This is considerably shorter than 
the time required for traditional methods including the 
time of transportation to the department of pathology and 
the interval between aspirations, which can take an average 
of over 30 minutes.67 When comparing telecytopathology 
with regular ROSE regarding diagnostic accuracy, one ret-
rospective study66 reported that the Kappa values of telecy-
topathology were less than those of ROSE for reaching the 
final diagnosis although the difference was not statistically 
significant. Thus, the author concluded that the application 
of telecytopathology could be a valid substitute for ROSE 
in EUS-guided tissue acquisition of solid pancreatic tu-
mors. The slight inferiority of telecytology compared with 
ROSE was considered to reflect the fact that accurate as-
sessment using telecytology largely depends on the initial 
screener who sends the images for review.68,69 The principle 
drawback of a static telecytology method is the subjectivity 
of image sampling, since a snapshot image may not truly 
be representative of the whole slide. Therefore, experienced 
physicians are recommended for sample preparation and 
image selection.
(3) Molecular analysis
Many molecular analyses for the detection of epigenetic 
and genetic alterations have been conducted using samples 
from EUS-guided tissue acquisition for a pancreatic tu-
mor.70-72 In addition, fluorescence in situ hybridization 
or digital image analysis are also performed for detecting 
chromosomal abnormalities in chromosomes 3, 7, 17, 
or 9p21, with 11% to 27% sensitivity.73,74 Among these, 
K-ras gene mutations are reported in more than 75% of 
pancreatic cancer cases,75 and it appears to be present in 
the early stages of the carcinogenesis process.76 Thus, K-
ras gene mutation analysis has been considered a possible 
biomarker for early detection of pancreatic cancer. In a 
recent meta-analysis of the diagnostic accuracy of K-ras 
mutation analysis for pancreatic cancer, the pooled sen-
sitivity and specificity of EUS-FNA with the traditional 
cytopathologic examination were 80.6% and 97%, respec-
tively. However, K-ras mutation analysis could be helpful 
for inconclusive results from index EUS-FNA by reducing 
the false-negative rate to 55.6% and the false-positive rate 
to 10.7%. Moreover, the repeat sampling rate was reduced 
from 12.5% to 6.8%.31 Therefore, the examination of the K-
ras mutation can be generally applied to inconclusive cases 
after index EUS-guided tissue acquisition. However, when 
K-ras mutation analysis is applied as an additional tool in 
the differential diagnosis of solid pancreatic tumors, clini-
cians must recognize that the significant reduction in the 
false-negative rate is counterbalanced by a relatively small 
increase in the false-positive rate. Thus, K-ras mutation 
analysis should always be cautiously interpreted within a 
clinical context. 
Table 5. Specific Indicators in Immunohistochemistry Staining47 
Marker for immunohistochemistry Target tumor
Cytokeratin (CK) 
Mucin core protein (MUC) 
Epithelial cell tumors
















Intraductal tubular or tubulo-papillary neoplasms
L26 B cell marker
UCHL1 T cell marker
LCA Malignant lymphoma
IgG4 subtype Autoimmune pancreatitis
Ziehl-Neelsen Peripancreatic tuberculous lymphadenopathy
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(4) Chemosensitivity and prediction of prognosis 
Many molecular abnormalities based on DNA, RNA, or 
proteins in pancreatic tumor tissues have been evaluated 
and determined to be indicators for prognosis77 and sensi-
tivity to chemoagents.78,79 Among these, a point mutation 
of the K-ras oncogene, which is found in more than 90% of 
pancreatic cancers, is reported as a negative prognostic fac-
tor.71,78 Overexpression of epidermal growth factor receptor 
in mRNA is also confirmed as a strong prognostic marker78 
which is easily detected in EUS-FNA samples.80 As well as 
prognostic factors, histologic samples using EUS-guided 
tissue acquisition for pancreatic cancer can predict the 
response to gemcitabine-based chemotherapy.81,82 Accord-
ing to a recent study by a French group, a transcriptome 
analysis from 17 xenografts of pancreatic cancer cells 
obtained by EUS-guided tissue acquisition could predict 
sensitivity to several anticancer drugs commonly used to 
treat pancreatic cancer.83 In addition, Wakatsuki et al.84 
used the adenosine triphosphate assay kit to determine the 
chemosensitivity of pancreatic cancer to chemotherapeutic 
agents. Following an indication of sensitivity to paclitaxel, 
they proceeded with this treatment, resulting in complete 
response and disappearance of pancreatic cancer. 
7. Adverse events of EUS-guided tissue acquisition 
(including FNA and FNB) and their prevention
Recommendation
EUS-guided tissue acquisition is a safe interven-
tion with relatively low risks of mortality (0.02%) and 
morbidity (0.98%). Procedure-related abdominal pain 
and post-procedure pancreatitis are the most common 
adverse events. Most unpredictable adverse events are 
mild in severity and self-limiting, while severe adverse 
events are very rare (level of evidence: moderate, grade 
of recommendation: strong).
1) Type and incidence of adverse events
Wang et al. 85 reported a systematic review including 
51 articles with a total of 10,941 patients who under-
went EUS-FNA. According to this systematic review, the 
overall morbidity rate related to EUS-FNA was 0.98% 
(107/10,941). Of the 8,246 patients who underwent EUS-
FNA for pancreatic lesions, including 909 with pancreatic 
cystic lesions and 7,337 with pancreatic solid tumors, pro-
cedure-related adverse events were reported in 85 patients 
(1.03%). Of the 36 (0.44% of all patients) patients with 
pancreatitis, 27 (75.0%) had mild, six (16.7%) had moder-
ate, and three (8.3%) had severe pancreatitis. Significant 
bleeding occurred in eight patients (0.1% of all patients). 
Furthermore, the overall incidence rates of fever and infec-
tion were 0.08%, and 0.02%, respectively (Table 6). Total 
procedure-related adverse events were reported in 60 pa-
tients (0.81%) with solid pancreatic tumors and 25 (2.75%) 
with pancreatic cyst (Table 6). 
2) Specific complications and their prevention
(1) Pancreatitis
Among 4,909 EUS-FNA samples analyzed in a U.S. 
multicenter survey of solid pancreatic tumors, acute pan-
creatitis was identified in 14 (0.29%).86 The targeted lesion 
was located in the head for the majority of the cases (n=12), 
whereas the lesion was located in the body and tail in one 
patient each. Furthermore, a recent prospective compara-
tive study87 for adverse events due to EUS-guided FNA 
of pancreatic cystic and solid lesions demonstrated that 
moderate or higher grade acute pancreatitis occurred in 
only one patient among 73 patients with pancreatic cystic 
lesions, while no patients with solid pancreatic lesions were 
found to have moderate or higher grade acute pancreatitis. 
Furthermore, two studies demonstrated that hyperamylas-
emia (defined as a serum amylase concentration above the 
upper limit of normal without any symptoms) occurred af-
ter EUS-guided tissue acquisition of pancreatic lesions.88,89 
The authors concluded that acute pancreatitis was present 
in less than 2% of these patients after EUS-FNA analysis, 
with silent hyperamylasemia being present in 3% to 11%. 
No predictive factor for hyperamylasemia resulting from 








Abdominal pain 31 (0.38) 24 (0.33)  7 (0.77)
Pancreatitis 36 (0.44) 26 (0.36) 10 (1.10)
Fever  7 (0.08)  4 (0.05)  3 (0.33)
Bleeding  8 (0.10)  5 (0.07)  3 (0.33)
Infection  2 (0.02) 0  2 (0.22)
Perforation  1 (0.01)  1 (0.01) 0
Bile leakage 0 0 0
Total 85 (1.03) 60 (0.81) 25 (2.75)
Data are presented as number (%).
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EUS-FNA has been identified. 
According to multivariate logistic regression risk fac-
tor analysis for acute pancreatitis,90 there were significant 
correlations with tumor sizes less than 20 mm (odds ratio 
[OR], 18.48; 95% CI, 3.55 to 96.17) and with PNET (OR, 
36.5; 95% CI, 1.73 to 771.83). Therefore, EUS-guided tis-
sue acquisition of small pancreatic masses suspected to be 
PENTs should also be approached with caution. Although 
the mechanism is not clear, procedure-related pancreatitis 
may occur by mechanical injury to the intervening normal 
pancreatic duct or parenchyma. Therefore, it is reasonable 
to ensure the shortest distance between the echoendoscope 
and target lesion when performing sample acquisition to 
avoid not only the main pancreatic duct but also dilated 
side branches; in particular, those located upstream from 
an obstructive mass causing high-pressure build-up of 
pancreatic juice. The puncture of such a duct may lead to 
extravasation of pancreatic juice.91
(2) Infectious complications
The incidence of bacteremia or even infection after 
EUS-guided tissue acquisition is very low, usually insignifi-
cant, and similar to that of diagnostic endoscopy including 
EUS without tissue acquisition.92 Furthermore, patients 
who develop bacteremia after EUS-guided tissue acquisi-
tion rarely manifest with a clinical infectious illness. A 
recent prospective study89 found three potential infectious 
events after EUS-FNA that were self-limited and recov-
ered within a few days using antibiotics. All three cases 
were pancreatic cystic lesions (total 73 patients) while 
no patients with solid pancreatic lesions complained of 
infectious symptoms such as fever. Although all patients 
received prophylactic antibiotics in this study, there is no 
strong evidence supporting this clinical practice. Although 
there is an argument supporting the administration of pro-
phylactic antibiotics in pancreatic cystic lesion,93 it only ap-
pears to be appropriate when it is impossible to completely 
aspirate all fluid components. 
In conclusion, current guidelines94 do not recommend 
using prophylactic antibiotics in patients undergoing EUS-
guided tissue acquisition of solid tumors, even in patients 
at high risk of infective endocarditis because the risk of in-
fection is not higher than other endoscopic interventions. 
However, endoscopists should consider the RR versus clin-
ical needs for prophylactic antibiotics when target lesions 
are pure cystic lesions or have partially cystic components. 
Although there is insufficient evidence to prove the need 
for prophylactic antibiotics, physicians should consider ad-
ministering antibiotics whenever the needle penetrates the 
bile duct, pancreatic duct, or major vascular structure.
(3) Intraluminal or extraluminal bleeding
Intraluminal bleeding following EUS-guided tissue 
acquisition is typically mild and self-limiting without clini-
cal consequences. Significant bleeding is very rare, but 
possible if large or major vasculatures are punctured or if 
patients have a coagulopathy.95 In a recent study96 using 
a Japanese nationwide administrative database regarding 
bleeding after EUS-FNA for pancreatic tumors, seven of 
3,090 patients (0.23%) required red blood cell transfu-
sion, endoscopic treatment, or angiographic intervention. 
In addition, three patients (0.10%) with severe bleeding 
required red blood cell transfusion within 3 days after the 
procedure. However, subgroup analysis revealed that the 
incidence of severe bleeding in low-volume centers was 
5-fold higher than in medium- and high-volume centers 
(p=0.045). Despite the lower incidence of intraluminal 
bleeding related to EUS-guided tissue acquisition, it can be 
easily controlled with local adrenaline injection or hemo-
static clips.97
Extra-luminal bleeding manifests as visibly expanding 
echo-poor regions near the target area, or confirmation 
of blood flow under color-Doppler ultrasonography, and 
has been reported to occur in 1.3% to 2.6% of all cases.98 
In addition, intra-cystic bleeding manifests as small hyper-
echoic areas that progress gradually over a few minutes, or 
blood flow within the cyst under color-Doppler ultraso-
nography, and has been reported to occur in 6% of EUS-
FNA procedures for pancreatic cysts.99 In this situation, en-
doscopists should terminate further movement or needle 
passes immediately, observe the apparent bleeding endo-
sonographically, and administer a short course of antibiot-
ics to prevent infection.99 Regarding antithrombotic treat-
ment, EUS-guided tissue acquisition should be avoided in 
patients taking oral anticoagulants such as thienopyridines 
(e.g., clopidogrel), but not aspirin or nonsteroidal anti-
inflammatory drugs according to recently issued American 
Society for Gastrointestinal Endoscopy (ASGE) and ESGE 
guidelines.87,100 If postponing or stopping antithrombotic 
therapy is not possible in patients with a high risk of 
thromboembolic events, consulting cardiologists regarding 
alternative agents and measurement of the risk-to-benefit 
ratio should be considered.
(4) Tumor seeding
Needle tract seeding after EUS-guided tissue acquisi-
tion has been considered to be an extremely rare adverse 
event,101 although there has been an increasing number of 
case reports in recent years.102 However, a recent study103 
of 301 patients who underwent distal pancreatectomy 
demonstrated that six patients (3.4%), among the 176 who 
underwent preoperative EUS-FNA, were diagnosed with 
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needle tract seeding. This rate of needle tract seeding is not 
negligible, although preoperative EUS-guided tissue acqui-
sition from the body or tail of the pancreas has not been 
shown to have a negative effect on recurrence-free survival 
of pancreatic cancer patients.
3) Do some technical factors influence the complication 
rate?
The relationship between the incidence of adverse 
events after EUS-guided tissue acquisition and needle 
size is an important issue. Theoretically, the incidence of 
adverse events with a larger diameter needle was expected 
to be higher than that using needles that were smaller in 
diameter. 
8. Learning EUS-guided tissue acquisition; do we 
recommend a minimum number of supervised 
procedures? 
Recommendation
In regard to EUS, the average trainee has to perform 
at least 225 EUS examinations with a total of 50 EUS-
guided tissue acquisition procedures for the achieve-
ment of competency in EUS-guided FNA or FNB (level 
of evidence: low, grade of recommendation: weak).
There is little available evidence regarding the minimal 
average number of performed procedures required to 
achieve competency in endoscopy. Several trials104-107 have 
reported the results of learning curves in EUS-FNA for 
solid pancreatic tumors, which are considered to be more 
complex than diagnostic EUS. In these trials, all trainees 
had performed at least 132–300 EUS-FNA procedures with 
the appropriate number of needle passes according to the 
ROSE guidelines. The sensitivity for the cytopathological 
diagnosis of pancreatic malignancy is closely related to the 
operator’s experience, of which 20 to 30 performed proce-
dures can lead to a sensitivity of 80%.56,108 
Recent guidelines109 regarding the endoscopic training 
by the ASGE recommend that at least 150 supervised EUS 
procedures be performed before the assessment of com-
petence. It is further recommended that these 150 cases 
include a minimum of 50 EUS-FNA, 75 pancreaticobiliary 
cases, 75 mucosal cancer staging cases, and evaluation of 
40 subepithelial lesions.110 However, a study concluded that 
150 cases might be inadequate for achieving competency 
and recommended that at least 225 hands-on procedures 
be performed before competence can be assessed.111
A more recent study112 demonstrated that the mini-
mum number of procedures that trainees should be of-
fered during their training to achieve competence in the 
core skills of EUS was approximately 225 cases. For EUS-
guided tissue acquisition, considerable variations were 
found between the trainees with respect to the speed of 
training;113 thus, this number should be considered to be 
the minimum before assessment of competence. A previ-
ous study evaluated 300 consecutive EUS-FNA procedures 
performed by a single endosonographer on solid pancre-
atic tumors over a 3-year period and reported that the pro-
portion of EUS-FNA procedures that required more than 
5 needle passes significantly decreased after 100 additional 
procedures and that the adverse events rate decreased after 
200 additional procedures.104
CONCLUSION
This guideline proposes a standard process for physi-
cians who perform EUS-guided tissue acquisition based on 
the available evidence at the time of preparation in order to 
prevent unnecessary or unsuitable medical treatments and 
to facilitate appropriate and practical recommendations 
for the tissue confirmation of solid pancreatic tumors. We 
aim to provide a suitable decision-making framework for 
the accurate diagnosis and appropriate management of 
patients with solid pancreatic tumors. This guideline is 
not intended to establish an absolute standard that physi-
cians should use to manage patients in real clinical settings 
but aims to assist physicians in making evidence-based 
judgments for the diagnosis of pancreatic solid tumors. 
Therefore, this guideline should not be used to support 
legal judgments, establish a legal standard of care or to 
encourage, advocate, require, or discourage any particular 
treatment. EUS-guided tissue acquisition has clearly been 
established as the first-line procedure for the diagnosis of 
solid pancreatic tumors and will continue to be improved 
as further research is conducted.
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